

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

<https://marketpublishers.com/r/G4CB483D0A1FEN.html>

Date: May 2025

Pages: 272

Price: US\$ 4,650.00 (Single User License)

ID: G4CB483D0A1FEN

Abstracts

Report Scope

This research report analyzes the global market for pharmaceutical drugs and its competitive landscape through 2029. It covers leading manufacturers of pharmaceutical drugs and the companies providing pharmaceutical services to biopharma and pharmaceutical firms), competitive intelligence and technological advances. The analysis includes recent developments in the product portfolios of major companies, as well as market share and rankings. The regulatory landscape analysis focuses on recent regulations in the U.S., Europe, and Japan. BCC Research estimated market size data for 2023 (base year) and forecast values for 2024 through the end of 2029. This report also examines drivers, restraints, and opportunities in the global market.

Report Includes

57 data tables and 152 additional tables

Evaluation of the current and future market potential of the pharmaceutical industry, featuring a look at the competitive landscape of the 50 leading pharmaceutical manufacturers

Analyses of the global market trends, with historical market revenue data (sales figures) from 2021-2024, and projected CAGRs through 2029

Discussion of the opportunities in the pharmaceutical industry, along with an evaluation of the competitive environment, regulatory landscape, and technological trends and advances

A look at the regulatory and pricing scenarios in the global market, with an emphasis on recently enacted regulations in the U.S., Europe and Japan

Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Analysis of patent activity, including key granted and published patents

Descriptive company profiles of the leading pharma manufacturers, including Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., and F. Hoffmann La Roche Ltd.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook
Scope of Report
Market Summary

CHAPTER 2 MARKET OVERVIEW

Overview
Stakeholders Involved in the Innovation Process
Future Perspectives
PESTEL Analysis
Porter's Five Forces Analysis
Supply Chain Analysis
Raw Materials Sourcing
Drug Manufacturing
QC and Compliance
Distribution
Regulatory Approval and Pricing Constraints
Sales and Marketing
Reverse Logistics and Returns

CHAPTER 3 MARKET DYNAMICS

Market Dynamics
Market Drivers
Rising Healthcare Expenditures
Focus on Rare Diseases and Orphan Drugs
Increasing Prevalence of Chronic Diseases and Aging Populations
Market Restraints
Stringent Regulatory Concerns
Loss of Exclusivity and Genericization
Lack of Oncology Professionals
Market Opportunities
Focus on Health Equity and Accessibility
AI in Oncology
Emerging Markets

Market Challenges
Price Pressures and Market Access
Environmental Impact and Sustainability
Counterfeit Drugs

CHAPTER 4 REGULATORY LANDSCAPE

Regulatory Framework
Regulatory Systems for Biopharmaceuticals
U.S.
Europe
Japan
Regulatory Systems for Pharmaceuticals
U.S.
EU Approval Process
Japan Approval Process
India Approval Process
Brazil Approval Process
GMP Compliance
Establishment Registration
Drug Registration and Listing
Local Agent Requirements
Responsibilities of the U.S. Agent

CHAPTER 5 EMERGING TECHNOLOGIES AND DEVELOPMENTS

Emerging Technologies
Artificial Intelligence (AI) and Machine Learning (ML)
Nanotechnology

3D PRINTING

Patent Analysis
Takeaways

CHAPTER 6 SUSTAINABILITY IN THE PHARMACEUTICAL DRUG INDUSTRY: AN ESG PERSPECTIVE

Sustainability in the Pharmaceutical Drugs Industry

Environmental
Social
Governance
Understanding ESG Data
Concluding Remarks from BCC Research

CHAPTER 7 COMPETITIVE INTELLIGENCE

Overview
Global Market Shares of Pharmaceutical Drug Companies
Strategies of Major Pharmaceutical Drug Manufacturers
Distribution Networks

CHAPTER 8 APPENDIX

Methodology
Abbreviations
Sources
Company Profiles
ABBOTT
ABBVIE INC.
ALNYLAM PHARMACEUTICALS INC.
AMGEN INC.
ARGENX
ASTELLAS PHARMA INC.
ASTRAZENECA
AUROBINDO PHARMA LTD.
BAUSCH HEALTH COMPANIES INC.
BAXTER
BAYER AG
BIOCON
BIOGEN
BIOMARIN
BIONTECH SE
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
CHUGAI PHARMACEUTICAL CO. LTD.
CSL
CSPC PHARMACEUTICAL GROUP LTD.

DAIICHI SANKYO CO. LTD.
DIVI'S LABORATORIES LTD.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
GALDERMA
GILEAD SCIENCES INC.
GRIFOLS S.A.
GSK PLC.
H. LUNDBECK A/S
INCYTE
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
LILLY
MERCK & CO. INC.
MERCK KGAA
MODERNA INC.
NEUROCRINE BIOSCIENCES INC.
NOVARTIS AG
NOVO NORDISK A/S
OTSUKA HOLDINGS CO. LTD.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
SINO BIOPHARMACEUTICAL CO. LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VERTEX PHARMACEUTICALS INC.
VIATRIS INC.
Emerging Players in the Market

List Of Tables

LIST OF TABLES

Summary Table : Global Market for Pharmaceutical Drugs, by Region, Through 2029

Table 1 : Global Health Expenditures, by Country, 2022

Table 2 : Global Incidence of All Cancers, by WHO Region, 2022–2050

Table 3 : Pharmaceutical Drug Patents Granted, by Leading Applicant, 2023

Table 4 : Pharmaceutical Drug Patents Granted, by Assignee Country/Region, January 2023–January 2025

Table 5 : ESG Rankings for Pharmaceutical Companies

Table 6 : Global Market Shares of Pharmaceutical Drugs, by Company, 2023

Table 7 : Best-Selling Pharmaceuticals, 2023

Table 8 : Total Revenue, Pharmaceutical Revenue, R&D Expenditure and Percentage of R&D in Revenue, by Drug Manufacturer, 2023

Table 9 : Abbreviations Used in this Report

Table 10 : Information Sources Used for this Report

Table 11 : Abbott: Company Snapshot

Table 12 : Abbott: Financial Performance, FY 2022 and 2023

Table 13 : Abbott: Product Portfolio

Table 14 : AbbVie Inc.: Company Snapshot

Table 15 : AbbVie Inc.: Financial Performance, FY 2022 and 2023

Table 16 : AbbVie Inc.: Product Portfolio

Table 17 : AbbVie Inc.: News/Key Developments, 2023-2025

Table 18 : Alnylam Pharmaceuticals Inc.: Company Snapshot

Table 19 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023

Table 20 : Alnylam Pharmaceuticals Inc.: Product Portfolio

Table 21 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024

Table 22 : Amgen Inc.: Company Snapshot

Table 23 : Amgen Inc.: Financial Performance, FY 2022 and 2023

Table 24 : Amgen Inc.: Product Portfolio

Table 25 : Amgen Inc.: News/Key Developments, 2023-2025

Table 26 : Argenx: Company Snapshot

Table 27 : Argenx: Financial Performance, FY 2022 and 2023

Table 28 : Argenx: Product Portfolio

Table 29 : Argenx: News/Key Developments, 2023 and 2024

Table 30 : Astellas Pharma Inc.: Company Snapshot

Table 31 : Astellas Pharma Inc.: Financial Performance, FY 2022 and 2023

Table 32 : Astellas Pharma Inc.: Product Portfolio

Table 33 : Astellas Pharma Inc.: News/Key Developments, 2023-2025
Table 34 : AstraZeneca: Company Snapshot
Table 35 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 36 : AstraZeneca: Product Portfolio
Table 37 : AstraZeneca: News/Recent Developments, 2023-2025
Table 38 : Aurobindo Pharma Ltd.: Company Snapshot
Table 39 : Aurobindo Pharma Ltd.: Financial Performance, FY 2022 and 2023
Table 40 : Aurobindo Pharma Ltd.: Product Portfolio
Table 41 : Aurobindo Pharma Ltd.: News/Key Developments, 2023 and 2024
Table 42 : Bausch Health Companies Inc.: Company Snapshot
Table 43 : Bausch Health Companies Inc.: Financial Performance, FY 2022 and 2023
Table 44 : Bausch Health Companies Inc.: Product Portfolio
Table 45 : Bausch Health Companies Inc.: News/Key Developments, 2023
Table 46 : Baxter: Company Snapshot
Table 47 : Baxter: Financial Performance, FY 2022 and 2023
Table 48 : Baxter: Product Portfolio
Table 49 : Baxter: News/Key Developments, 2023 and 2024
Table 50 : Bayer AG: Company Snapshot
Table 51 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 52 : Bayer AG: Product Portfolio
Table 53 : Bayer AG: News/Key Developments, 2023-2025
Table 54 : Biocon: Company Snapshot
Table 55 : Biocon: Financial Performance, FY 2022 and 2023
Table 56 : Biocon: Product Portfolio
Table 57 : Biocon: News/Key Developments, 2023-2024
Table 58 : Biogen: Company Snapshot
Table 59 : Biogen: Financial Performance, FY 2022 and 2023
Table 60 : Biogen: Product Portfolio
Table 61 : Biogen: News/Key Developments, 2023-2025
Table 62 : BioMarin: Company Snapshot
Table 63 : BioMarin: Financial Performance, FY 2022 and 2023
Table 64 : BioMarin: Product Portfolio
Table 65 : BioMarin: News/Key Developments, 2021-2024
Table 66 : BioNTech SE: Company Snapshot
Table 67 : BioNTech SE: Financial Performance, FY 2022 and 2023
Table 68 : BioNTech SE: Product Portfolio
Table 69 : BioNTech: News/Key Developments, 2023-2025
Table 70 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 71 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022

and 2023

Table 72 : Boehringer Ingelheim International GmbH: Product Portfolio

Table 73 : Boehringer Ingelheim International GmbH: News/Key Developments, 2023-2025

Table 74 : Bristol-Myers Squibb Co.: Company Snapshot

Table 75 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023

Table 76 : Bristol-Myers Squibb Co.: Product Portfolio

Table 77 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024

Table 78 : Chugai Pharmaceutical Co. Ltd.: Company Snapshot

Table 79 : Chugai Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023

Table 80 : Chugai Pharmaceutical Co. Ltd.: Product Portfolio

Table 81 : Chugai Pharmaceutical Co. Ltd.: News/Key Developments, 2023-2025

Table 82 : CSL: Company Snapshot

Table 83 : CSL: Financial Performance, FY 2022 and 2023

Table 84 : CSL: Product Portfolio

Table 85 : CSL: News/Key Developments, 2023-2025

Table 86 : CSPC Pharmaceutical Group Ltd.: Company Snapshot

Table 87 : CSPC Pharmaceutical Group Ltd.: Financial Performance, FY 2022 and 2023

Table 88 : CSPC Pharmaceutical Group Ltd.: Product Portfolio

Table 89 : CSPC Pharmaceutical Group Ltd.: News/Key Developments, 2024

Table 90 : Daiichi Sankyo Co. Ltd.: Company Snapshot

Table 91 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023

Table 92 : Daiichi Sankyo Co. Ltd.: Product Portfolio

Table 93 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2025

Table 94 : Divi's Laboratories Ltd.: Company Snapshot

Table 95 : Divi's Laboratories Ltd.: Financial Performance, FY 2022 and 2023

Table 96 : Divi's Laboratories Ltd.: Product Portfolio

Table 97 : Eisai Co. Ltd.: Company Snapshot

Table 98 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023

Table 99 : Eisai Co. Ltd.: Product Portfolio

Table 100 : Eisai Co. Ltd.: News/Recent Developments, 2023-2025

Table 101 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 102 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024

Table 103 : F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 104 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023–2025

Table 105 : Galderma: Company Snapshot

Table 106 : Galderma: Financial Performance, FY 2022 and 2023

Table 107 : Galderma: Product Portfolio

Table 108 : Galderma: News/Key Developments, 2024
Table 109 : Gilead Sciences Inc.: Company Snapshot
Table 110 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 111 : Gilead Sciences Inc.: Product Portfolio
Table 112 : Gilead Sciences Inc.: News/Key Developments, 2023–2025
Table 113 : Grifols S.A: Company Snapshot
Table 114 : Grifols S.A.: Financial Performance, FY 2022 and 2023
Table 115 : Grifols S.A: Product Portfolio
Table 116 : Grifols S.A: News/Key Developments, 2023-2025
Table 117 : GSK plc.: Company Snapshot
Table 118 : GSK plc.: Financial Performance, FY 2022 and 2023
Table 119 : GSK plc.: Product Portfolio
Table 120 : GSK plc.: News/Key Developments, 2023–2025
Table 121 : H. Lundbeck A/S: Company Snapshot
Table 122 : H. Lundbeck A/S: Financial Performance, FY 2022 and 2023
Table 123 : H. Lundbeck A/S: Product Portfolio
Table 124 : H. Lundbeck A/S: News/Key Developments, 2022-2024
Table 125 : Incyte: Company Snapshot
Table 126 : Incyte: Financial Performance, FY 2022 and 2023
Table 127 : Incyte: Product Portfolio
Table 128 : Incyte: News/Key Developments, 2023-2025
Table 129 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 130 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 131 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 132 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
Table 133 : Johnson & Johnson Services Inc.: Company Snapshot
Table 134 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 135 : Johnson & Johnson Services Inc.: Product Portfolio
Table 136 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 137 : Les Laboratoires Servier: Company Snapshot
Table 138 : Les Laboratoires Servier: Financial Performance, FY 2022 and 2023
Table 139 : Les Laboratoires Servier: Product Portfolio
Table 140 : Les Laboratoires Servier: News/Key Developments, 2023-2025
Table 141 : Lilly: Company Snapshot
Table 142 : Lilly: Financial Performance, FY 2022 and 2023
Table 143 : Lilly: Product Portfolio
Table 144 : Lilly: News/Key Developments, 2022–2025
Table 145 : Merck & Co. Inc.: Company Snapshot

Table 146 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 147 : Merck & Co. Inc.: Product Portfolio
Table 148 : Merck & Co. Inc.: News/Key Developments, 2021–2024
Table 149 : Merck KGaA: Company Snapshot
Table 150 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 151 : Merck KGaA: Product Portfolio
Table 152 : Merck KGaA: News/Key Developments, 2023-2025
Table 153 : Moderna Inc.: Company Snapshot
Table 154 : Moderna Inc.: Financial Performance, FY 2022 and 2023
Table 155 : Moderna Inc.: Product Portfolio
Table 156 : Moderna Inc.: News/Key Developments, 2023 and 2024
Table 157 : Neurocrine Biosciences Inc: Company Snapshot
Table 158 : Neurocrine Biosciences Inc: Financial Performance, FY 2022 and 2023
Table 159 : Neurocrine Biosciences Inc: Product Portfolio
Table 160 : Neurocrine Biosciences Inc: News/Key Developments, 2023-2025
Table 161 : Novartis AG: Company Snapshot
Table 162 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 163 : Novartis AG: Product Portfolio
Table 164 : Novartis AG: News/Key Developments, 2022-2024
Table 165 : Novo Nordisk A/S: Company Snapshot
Table 166 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 167 : Novo Nordisk A/S: Product Portfolio
Table 168 : Novo Nordisk A/S: News/Key Developments, 2023-2025
Table 169 : Otsuka Holdings Co. Ltd.: Company Snapshot
Table 170 : Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 171 : Otsuka Holdings Co. Ltd.: Product Portfolio
Table 172 : Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024
Table 173 : Pfizer Inc.: Company Snapshot
Table 174 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 175 : Pfizer Inc.: Product Portfolio
Table 176 : Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 177 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 178 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 179 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 180 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 181 : Sanofi: Company Snapshot
Table 182 : Sanofi: Financial Performance, FY 2022 and 2023
Table 183 : Sanofi: Product Portfolio

Table 184 : Sanofi: News/Key Developments, 2022–2025
Table 185 : Sino Biopharmaceutical Co. Ltd.: Company Snapshot
Table 186 : Sino Biopharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 187 : Sino Biopharmaceutical Co. Ltd.: Product Portfolio
Table 188 : Sino Biopharmaceutical Co. Ltd.: News/Key Developments, 2023-2025
Table 189 : Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 190 : Sun Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 191 : Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 192 : Sun Pharmaceutical Industries Ltd.: News/Key Developments, 2022-2024
Table 193 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 194 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 195 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 196 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023 and 2024
Table 197 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 198 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 199 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 200 : Vertex Pharmaceuticals Inc.: Company Snapshot
Table 201 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 202 : Vertex Pharmaceuticals Inc.: Product Portfolio
Table 203 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2022-2025
Table 204 : Viatris Inc.: Company Snapshot
Table 205 : Viatris Inc.: Financial Performance, FY 2022 and 2023
Table 206 : Viatris Inc.: Product Portfolio
Table 207 : Viatris Inc.: News/Key Developments, 2023 and 2024
Table 208 : Few Emerging Players in the Market

List Of Figures

LIST OF FIGURES

Summary Figure : Global Market Shares of Pharmaceutical Drugs, by Region, 2023

Figure 1 : Supply Chain of the Pharmaceutical Drugs Industry

Figure 2 : Pharmaceutical Drug Industry Market Dynamics

Figure 3 : Trends and Emerging Technologies in the Pharmaceutical Drug Industry

Figure 4 : Global Market Shares of Leading Pharmaceutical Drug Companies, 2023

Figure 5 : Abbott: Revenue Share, by Business Unit, FY 2023

Figure 6 : Abbott: Revenue Share, by Country/Region, FY 2023

Figure 7 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023

Figure 8 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023

Figure 9 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023

Figure 10 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023

Figure 11 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023

Figure 12 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023

Figure 13 : Argenx: Revenue Share, by Country/Region, FY 2023

Figure 14 : Astellas Pharma Inc.: Revenue Share, by Business Unit, FY 2023

Figure 15 : Astellas Pharma Inc.: Revenue Share, by Country/Region, FY 2023

Figure 16 : AstraZeneca: Revenue Share, by Business Unit, FY 2023

Figure 17 : AstraZeneca: Revenue Share, by Region/Country, FY 2023

Figure 18 : Aurobindo Pharma Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 19 : Aurobindo Pharma Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 20 : Bausch Health Companies Inc.: Revenue Share, by Business Unit, FY 2023

Figure 21 : Bausch Health Companies Inc.: Revenue Share, by Country/Region, FY 2023

Figure 22 : Baxter: Revenue Share, by Business Unit, FY 2023

Figure 23 : Baxter: Revenue Share, by Country/Region, FY 2023

Figure 24 : Bayer AG: Revenue Share, by Business Unit, FY 2023

Figure 25 : Bayer AG: Revenue Share, by Country/Region, FY 2023

Figure 26 : Biocon: Revenue Share, by Business Unit, FY 2023

Figure 27 : Biogen: Revenue Share, by Business Unit, FY 2023

Figure 28 : Biogen: Revenue Share, by Country/Region, FY 2023

Figure 29 : BioMarin: Revenue Share, by Business Unit, FY 2023

Figure 30 : BioMarin: Revenue Share, by Country/Region, FY 2023

Figure 31 : BioNTech SE: Revenue Share, by Business Unit, FY 2023

Figure 32 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023

Figure 33 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023

Figure 34 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023

Figure 35 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023

Figure 36 : Chugai Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023

Figure 37 : CSL: Revenue Share, by Business Unit, FY 2023

Figure 38 : CSL: Revenue Share, by Region, FY 2023

Figure 39 : CSPC Pharmaceutical Group Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 40 : CSPC Pharmaceutical Group Ltd.: Revenue Share, by Region, FY 2023

Figure 41 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 42 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Region, FY 2023

Figure 43 : Divi's Laboratories Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 44 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 45 : Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023

Figure 46 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024

Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024

Figure 48 : Galderma: Revenue Share, by Business Unit, FY 2023

Figure 49 : Galderma: Revenue Share, by Country/Region, FY 2023

Figure 50 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023

Figure 51 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023

Figure 52 : Grifols S.A: Revenue Share, by Business Unit, FY 2023

Figure 53 : Grifols S.A.: Revenue Share, by Region, FY 2023

Figure 54 : GSK plc.: Revenue Share, by Business Unit, FY 2023

Figure 55 : GSK plc.: Revenue Share, by Country/Region, FY 2023

Figure 56 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023

Figure 57 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023

Figure 58 : Incyte: Revenue Share, by Business Unit, FY 2023

Figure 59 : Jazz Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023

Figure 60 : Jazz Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023

Figure 61 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023

Figure 62 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023

Figure 63 : Les Laboratoires Servier: Revenue Share, by Business Unit, FY 2023

Figure 64 : Les Laboratoires Servier: Revenue Share, by Region, FY 2023

Figure 65 : Lilly: Revenue Share, by Business Unit, FY 2023

Figure 66 : Lilly: Revenue Share, by Country/Region, FY 2023

Figure 67 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023

- Figure 68 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 69 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
- Figure 70 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
- Figure 71 : Moderna Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 72 : Neurocrine Biosciences Inc: Revenue Share, by Business Unit, FY 2023
- Figure 73 : Novartis AG: Revenue Share, by Business Unit, FY 2023
- Figure 74 : Novartis AG: Revenue Share, by Country/Region, FY 2023
- Figure 75 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
- Figure 76 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
- Figure 77 : Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023
- Figure 78 : Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023
- Figure 79 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 80 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 81 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 82 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 83 : Sanofi: Revenue Share, by Business Unit, FY 2023
- Figure 84 : Sanofi: Revenue Share, by Country/Region, FY 2023
- Figure 85 : Sino Biopharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
- Figure 86 : Sino Biopharmaceutical Co. Ltd.: Revenue Share, by Country/Region, FY 2023
- Figure 87 : Sun Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
- Figure 88 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023
- Figure 89 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023
- Figure 90 : Teva Pharmaceutical Industries Ltd: Revenue Share, by Business Unit, FY 2023
- Figure 91 : Teva Pharmaceutical Industries Ltd: Revenue Share, by Country/Region, FY 2023
- Figure 92 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 93 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 94 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 95 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023

I would like to order

Product name: Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

Product link: <https://marketpublishers.com/r/G4CB483D0A1FEN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4CB483D0A1FEN.html>